Anticancer drugs targeting the mitochondrial electron transport chain

Antioxidants and Redox Signaling

Volumn 15, Issue 12, 2011, Pages 2951-2974

  Rohlena, Jakub ^a   Dong, Lan Feng ^b   Ralph, Stephen J ^b   Neuzil, Jiri ^a,b  

^a INSTITUTE OF BIOTECHNOLOGY   (Czech Republic)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ADENINE NUCLEOTIDE TRANSLOCASE; ALPHA TOCOPHEROL SUCCINATE; ANTIMYCIN A1; ARSENIC TRIOXIDE; BETULIC ACID; CYTOCHROME C OXIDASE; DEGUELIN; DEOXYCORTICOSTERONE ACETATE; DEOXYGLUCOSE; FIALURIDINE; GOSSYPOL; HEXOKINASE; ISOTHIOCYANIC ACID; LONIDAMINE; MENADIONE; METFORMIN; MITOCHONDRIAL DNA; PROTEIN BCL 2; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RHODAMINE 123; SUCCINATE DEHYDROGENASE; TAMOXIFEN; THIOL; UBIQUINOL CYTOCHROME C REDUCTASE; UNINDEXED DRUG; VOLTAGE DEPENDENT ANION CHANNEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CITRIC ACID CYCLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG TARGETING; HUMAN; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY CHAIN;

ANIMALS; ANTINEOPLASTIC AGENTS; ELECTRON TRANSPORT; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 80155134278     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.3990     Document Type: Article

References (229)

1. Adam-Vizi V and Chinopoulos C. Bioenergetics and the formation of mitochondrial reactive oxygen species. Trends Pharmacol Sci 27: 639-645, 2006.
2. Akazawa A, Nishikawa K, Suzuki K, Asano R, Kumadaki I, Satoh H, Hagiwara K, Shin SJ, and Yano T. Induction of apoptosis in a human breast cancer cell overexpressing ErbB-2 receptor by alpha-tocopheryloxybutyric acid. Jpn J Pharmacol 89: 417-421, 2002.
3. Albini A, Dell'Eva R, Vene R, Ferrari N, Buhler DR, Noonan DM, and Fassina G. Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets. FASEB J 20: 527-529, 2006.
4. Alleva R, Benassi MS, Tomasetti M, Gellert N, Ponticelli F, Borghi B, Picci P, and Neuzil J. Alpha-tocopheryl succinate induces cytostasis and apoptosis in osteosarcoma cells: The role of E2F1. Biochem Biophys Res Commun 331: 1515-1521, 2005.
5. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, and Young IG. Sequence and organization of the human mitochondrial genome. Nature 290: 457-465, 1981.
6. Asayama S, Kawamura E, Nagaoka S, and Kawakami H. Design of manganese porphyrin modified with mitochondrial signal peptide for a new antioxidant. Mol Pharm 3: 468-470, 2006.
7. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, and Kim AL. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224: 274-283, 2007.
8. Baggetto LG and Testa-Parussini R. Role of acetoin on the regulation of intermediate metabolism of Ehrlich ascites tumor mitochondria: Its contribution to membrane cholesterol enrichment modifying passive proton permeability. Arch Biochem Biophys 283: 241-248, 1990.
9. Ballot C, Kluza J, Lancel S, Martoriati A, Hassoun SM, Mortier L, Vienne JC, Briand G, Formstecher P, Bailly C, Neviere R, and Marchetti P. Inhibition of mitochondrial respiration mediates apoptosis induced by the anti-tumoral alkaloid lamellarin D. Apoptosis 15: 769-781, 2010.
10. Ballot C, Kluza J, Martoriati A, Nyman U, Formstecher P, Joseph B, Bailly C, and Marchetti P. Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid lamellarin D. Mol Cancer Ther 8: 3307-3317, 2009.
11. Baracca A, Chiaradonna F, Sgarbi G, Solaini G, Alberghina L, and Lenaz G. Mitochondrial complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells. Biochim Biophys Acta 1797: 314-323, 2010.
12. Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Metivier D, Marchetti P, Brenner C, and Kroemer G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20: 7579-7587, 2001.
13. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF, and Bost F. Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475, 2010.
14. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, Figg WD, Tompkins A, Linehan WM, Kohler D, Steinberg SM, and Blagosklonny MV. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. Clin Cancer Res 5: 2366-2373, 1999.
15. Bernal SD, Lampidis TJ, McIsaac RM, and Chen LB. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science 222: 169-172, 1983.
16. Bernal SD, Lampidis TJ, Summerhayes IC, and Chen LB. Rhodamine-123 selectively reduces clonal growth of carcinoma cells in vitro. Science 218: 1117-1119, 1982.
17. Berrisford JM and Sazanov LA. Structural basis for the mechanism of respiratory complex I. J Biol Chem 284: 29773-29783, 2009.
18. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, and Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306, 2000.
19. Biasutto L, Mattarei A, Marotta E, Bradaschia A, Sassi N, Garbisa S, Zoratti M, and Paradisi C. Development of mitochondria-targeted derivatives of resveratrol. Bioorg Med Chem Lett 18: 5594-5597, 2008.
20. Blatt NB, Boitano AE, Lyssiotis CA, Opipari AW Jr, and Glick GD. Bz-423 superoxide signals apoptosis via selective activation of JNK, Bak, and Bax. Free Radic Biol Med 45: 1232-1242, 2008.
21. Boitano A, Ellman JA, Glick GD, and Opipari AW, Jr. The proapoptotic benzodiazepine Bz-423 affects the growth and survival of malignant B cells. Cancer Res 63: 6870-6876, 2003.
22. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, and Michelakis ED. A mitochondria-K + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11: 37-51, 2007.
23. Bonsi P, Cuomo D, Martella G, Sciamanna G, Tolu M, Calabresi P, Bernardi G, and Pisani A. Mitochondrial toxins in basal ganglia disorders: From animal models to therapeutic strategies. Curr Neuropharmacol 4: 69-75, 2006.
24. Brand MD. The sites and topology of mitochondrial superoxide production. Exp Gerontol 45: 466-472, 2010.
25. Britten CD, Rowinsky EK, Baker SD, Weiss GR, Smith L, Stephenson J, Rothenberg M, Smetzer L, Cramer J, Collins W, Von Hoff DD, and Eckhardt SG. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res 6: 42-49, 2000.
26. Brown KK, Cox AG, and Hampton MB. Mitochondrial respiratory chain involvement in peroxiredoxin 3 oxidation by phenethyl isothiocyanate and auranofin. FEBS Lett 584: 1257-1262, 2010.
27. Bullough DA, Ceccarelli EA, Roise D, and Allison WS. Inhibition of the bovine-heart mitochondrial F1-ATPase by cationic dyes and amphipathic peptides. Biochim Biophys Acta 975: 377-383, 1989.
28. Bustamante E, Morris HP, and Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 256: 8699-8704, 1981.
29. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, and Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752, 2007.
30. Caboni P, Sherer TB, Zhang N, Taylor G, Na HM, Greenamyre JT, and Casida JE. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem Res Toxicol 17: 1540-1548, 2004.
31. Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, and Kaufmann SH. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 102: 4512-4519, 2003.
32. Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, and Kaufmann SH. Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and-independent imatinib resistance. Blood 107: 2501-2506, 2006.
33. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG, and Kalyanaraman B. Doxorubicin inactivates myocardial cytochrome c oxidase in rats: Cardioprotection by Mito-Q. Biophys J 96: 1388-1398, 2009.
34. Check Hayden E. Cancer complexity slows quest for cure. Nature 455: 148, 2008.
35. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, and Lesnefsky EJ. Production of reactive oxygen species by mitochondria: Central role of complex III. J Biol Chem 278: 36027-36031, 2003.
36. Chen Z, Zhang H, Lu W, and Huang P. Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 1787: 553-560, 2009.
37. Choi WS, Palmiter RD, and Xia Z. Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol 192: 873-882, 2011.
38. Chong CR and Chabner BA. Mysterious metformin. Oncologist 14: 1178-1181, 2009.
39. Chun KH, Kosmeder JW, 2nd, Sun S, Pezzuto JM, Lotan R, Hong WK, and Lee HY. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J Natl Cancer Inst 95: 291-302, 2003.
40. Crofts AR. The cytochrome bc1 complex: Function in the context of structure. Annu Rev Physiol 66: 689-733, 2004.
41. Croxtall JD, Emmas C, White JO, Choudhary Q, and Flower RJ. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells. Biochem Pharmacol 47: 197-202, 1994.
42. Cuchelkar V, Kopeckova P, and Kopecek J. Novel HPMA copolymer-bound constructs for combined tumor and mitochondrial targeting. Mol Pharm 5: 776-786, 2008.
43. Cuezva JM, Sanchez-Arago M, Sala S, Blanco-Rivero A, and Ortega AD. A message emerging from development: The repression of mitochondrial beta-F1-ATPase expression in cancer. J Bioenerg Biomembr 39: 259-265, 2007.
44. D'Alessio M, De Nicola M, Coppola S, Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P, Ciriolo MR, Bergamaschi A, Magrini A, and Ghibelli L. Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis. FASEB J 19: 1504-1506, 2005.
45. Dang CV, Kim JW, Gao P, and Yustein J. The interplay between MYC and HIF in cancer. Nat Rev Cancer 8: 51-56, 2008.
46. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, and Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744, 2009.
47. Dasmahapatra G, Nguyen TK, Dent P, and Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leuk Res 30: 1263-1272, 2006.
48. Davis RA, Carroll AR, Pierens GK, and Quinn RJ. New lamellarin alkaloids from the australian ascidian, didemnum chartaceum. J Nat Prod 62: 419-424, 1999.
49. Davis S, Weiss MJ, Wong JR, Lampidis TJ, and Chen LB. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 260: 13844-13850, 1985.
50. Degli Esposti M. Inhibitors of NADH-ubiquinone reductase: An overview. Biochim Biophys Acta 1364: 222-235, 1998.
51. Dell'Eva R, Ambrosini C, Minghelli S, Noonan DM, Albini A, and Ferrari N. The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-kappaB pathway. Carcinogenesis 28: 404-413, 2007.
52. Devenish RJ, Prescott M, and Rodgers AJ. The structure and function of mitochondrial F1F0-ATP synthases. Int Rev Cell Mol Biol 267: 1-58, 2008.
53. Di Monte DA. The environment and Parkinson's disease: Is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2: 531-538, 2003.
54. Don AS, Kisker O, Dilda P, Donoghue N, Zhao X, Decollogne S, Creighton B, Flynn E, Folkman J, and Hogg PJ. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 3: 497-509, 2003.
55. Donapaty S, Louis S, Horvath E, Kun J, Sebti SM, and Malafa MP. RRR-alpha-tocopherol succinate down-regulates oncogenic Ras signaling. Mol Cancer Ther 5: 309-316, 2006.
56. Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B, Goodwin J, Brunk UT, Witting PK, Moreno-Sanchez R, Scheffler IE, Ralph SJ, and Neuzil J. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin Cancer Res 15: 1593-1600, 2009.
57. Dong LF, Jameson VJ, Tilly D, Cerny J, Mahdavian E, Marin-Hernandez A, Hernandez-Esquivel L, Rodriguez-Enriquez S, Stursa J, Witting PK, Stantic B, Rohlena J, Truksa J, Kluckova K, Dyason JC, Ledvina M, Salvatore BA, Moreno-Sanchez R, Coster MJ, Ralph SJ, Smith RA, and Neuzil J. Mitochondrial targeting of vitamin E succinate enhances its pro-apoptotic and anticancer activity via mitochondrial complex II. J Biol Chem 286: 3717-3728, 2011.
58. Dong LF, Jameson VJ, Tilly D, Prochazka L, Rohlena J, Valis K, Truksa J, Zobalova R, Mahdavian E, Kluckova K, Stantic M, Stursa J, Freeman R, Witting PK, Norberg E, Goodwin J, Salvatore BA, Novotna J, Turanek J, Ledvina M, Hozak P, Zhivotovsky B, Coster MJ, Ralph SJ, Smith RA, and Neuzil J. Mitochondrial targeting of alphatocopheryl succinate enhances its pro-apoptotic efficacy: A new paradigm of efficient cancer therapy. Free Radic Biol Med 50: 1546-1555, 2011.
59. Dong LF, Low P, Dyason JC, Wang XF, Prochazka L, Witting PK, Freeman R, Swettenham E, Valis K, Liu J, Zobalova R, Turanek J, Spitz DR, Domann FE, Scheffler IE, Ralph SJ, and Neuzil J. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 27: 4324-4335, 2008.
60. Drechsel DA and Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson's disease. Free Radic Biol Med 44: 1873-1886, 2008.
61. Drose S and Brandt U. The mechanism of mitochondrial superoxide production by the cytochrome bc1 complex. J Biol Chem 283: 21649-21654, 2008.
62. Efremov RG, Baradaran R, and Sazanov LA. The architecture of respiratory complex I. Nature 465: 441-445, 2010.
63. Eguchi Y, Shimizu S, and Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 57: 1835-1840, 1997.
64. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, Krajewski S, Lombardo CR, Rao R, Ruoslahti E, Bredesen DE, and Pasqualini R. Anticancer activity of targeted pro-apoptotic peptides. Nature Medicine 5: 1032-1038, 1999.
65. Facompre M, Tardy C, Bal-Mahieu C, Colson P, Perez C, Manzanares I, Cuevas C, and Bailly C. Lamellarin D: A novel potent inhibitor of topoisomerase I. Cancer Res 63: 7392-7399, 2003.
66. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, and Leder P. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2: 29-42, 2002.
67. Fato R, Bergamini C, Bortolus M, Maniero AL, Leoni S, Ohnishi T, and Lenaz G. Differential effects of mitochondrial complex I inhibitors on production of reactive oxygen species. Biochim Biophys Acta 1787: 384-392, 2009.
68. Fato R, Bergamini C, Leoni S, Strocchi P, and Lenaz G. Generation of reactive oxygen species by mitochondrial complex I: Implications in neurodegeneration. Neurochem Res 33: 2487-2501, 2008.
69. Festjens N, Kalai M, Smet J, Meeus A, Van Coster R, Saelens X, and Vandenabeele P. Butylated hydroxyanisole is more than a reactive oxygen species scavenger. Cell Death Differ 13: 166-169, 2006.
70. Fruehauf JP and Meyskens FL, Jr. Reactive oxygen species: A breath of life or death? Clin Cancer Res 13: 789-794, 2007.
71. Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, and Semenza GL. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129: 111-122, 2007.
72. Fulda S, Galluzzi L, and Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464, 2010.
73. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, and Debatin KM. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J Biol Chem 273: 33942-33948, 1998.
74. Gallego MA, Ballot C, Kluza J, Hajji N, Martoriati A, Castera L, Cuevas C, Formstecher P, Joseph B, Kroemer G, Bailly C, and Marchetti P. Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway. Oncogene 27: 1981-1992, 2008.
75. Galluzzi L, Larochette N, Zamzami N, and Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25: 4812-4830, 2006.
76. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, and Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13: 1423-1433, 2006.
77. Gledhill JR, Montgomery MG, Leslie AG, and Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc Natl Acad Sci USA 104: 13632-13637, 2007.
78. Gogvadze V, Norberg E, Orrenius S, and Zhivotovsky B. Involvement of Ca(2 + ) and ROS in alpha-tocopheryl succinate-induced mitochondrial permeabilization. Int J Cancer 127: 1823-1832, 2010.
79. Gogvadze V, Orrenius S, and Zhivotovsky B. Mitochondria in cancer cells: What is so special about them? Trends Cell Biol 18: 165-173, 2008.
80. Gogvadze V, Orrenius S,and Zhivotovsky B. Mitochondria as targets for cancer chemotherapy. Semin Cancer Biol 19: 57-66, 2009.
81. Gomez-Lazaro M, Galindo MF, Melero-Fernandez de Mera RM, Fernandez-Gomez FJ, Concannon CG, Segura MF, Comella JX, Prehn JH, and Jordan J. Reactive oxygen species and p38 mitogen-activated protein kinase activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Mol Pharmacol 71: 736-743, 2007.
82. Gong Y, Sohn H, Xue L, Firestone GL, and Bjeldanes LF. 3,3'-Diindolylmethane is a novel mitochondrial H( + )-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells. Cancer Res 66: 4880-4887, 2006.
83. Gottlieb E and Tomlinson IP. Mitochondrial tumour suppressors: A genetic and biochemical update. Nat Rev Cancer 5: 857-866, 2005.
84. Gough DJ, Corlett A, Schlessinger K, Wegrzyn J, Larner AC, and Levy DE. Mitochondrial STAT3 supports Rasdependent oncogenic transformation. Science 324: 1713-1716, 2009.
85. Graham DJ, Green L, Senior JR, and Nourjah P. Troglitazoneinduced liver failure: A case study. Am J Med 114: 299-306, 2003.
86. Grivennikova VG and Vinogradov AD. Generation of superoxide by the mitochondrial Complex I. Biochim Biophys Acta 1757: 553-561, 2006.
87. Hail N, Jr. And Lotan R. Apoptosis induction by the natural product cancer chemopreventive agent deguelin is mediated through the inhibition of mitochondrial bioenergetics. Apoptosis 9: 437-447, 2004.
88. Harikumar KB and Aggarwal BB. Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle 7: 1020-1035, 2008.
89. Harikumar KB, Kunnumakkara AB, Ahn KS, Anand P, Krishnan S, Guha S, and Aggarwal BB. Modification of the cysteine residues in IkappaBalpha kinase and NF-kappaB (p65) by xanthohumol leads to suppression of NF-kappaBregulated gene products and potentiation of apoptosis in leukemia cells. Blood 113: 2003-2013, 2009.
90. Herr HW, Huffman JL, Huryk R, Heston WD, Melamed MR, and Whitmore WF, Jr. Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma. Cancer Res 48: 2061-2063, 1988.
91. Hilf R. Mitochondria are targets of photodynamic therapy. J Bioenerg Biomembr 39: 85-89, 2007.
92. Huang LS, Sun G, Cobessi D, Wang AC, Shen JT, Tung EY, Anderson VE, and Berry EA. 3-nitropropionic acid is a suicide inhibitor of mitochondrial respiration that, upon oxidation by complex II, forms a covalent adduct with a catalytic base arginine in the active site of the enzyme. J Biol Chem 281: 5965-5972, 2006.
93. Huang P, Feng L, Oldham EA, Keating MJ, and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407: 390-395, 2000.
94. Iwata S, Lee JW, Okada K, Lee JK, Iwata M, Rasmussen B, Link TA, Ramaswamy S, and Jap BK. Complete structure of the 11-subunit bovine mitochondrial cytochrome bc1 complex. Science 281: 64-71, 1998.
95. Jemal A, Bray F, Center MM, Ferlay J, Ward E, and Forman D. Global cancer statistics. CA: Cancer J Clin 61: 69-90, 2011.
96. Jemal A, Siegel R, Xu J, and Ward E. Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
97. Johnson KM, Cleary J, Fierke CA, Opipari AW, Jr., and Glick GD. Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase. ACS Chem Biol 1: 304-308, 2006.
98. Johnson LV, Walsh ML, and Chen LB. Localization of mitochondria in living cells with rhodamine 123. Proc Natl Acad Sci USA 77: 990-994, 1980.
99. Jones LW, Narayan KS, Shapiro CE, and Sweatman TW. Rhodamine-123: Therapy for hormone refractory prostate cancer, a phase I clinical trial. J Chemother 17: 435-440, 2005.
100. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, and Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806, 2008.
101. Junge W, Sielaff H, and Engelbrecht S. Torque generation and elastic power transmission in the rotary F(O)F(1)-ATPase. Nature 459: 364-370, 2009.
102. Kang MH and Reynolds CP. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15: 1126-1132, 2009.
103. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, and Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem 276: 4588-4596, 2001.
104. Kim WY, Oh SH, Woo JK, Hong WK, and Lee HY. Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha. Cancer Res 69: 1624-1632, 2009.
105. Kluza J, Gallego MA, Loyens A, Beauvillain JC, Sousa-Faro JM, Cuevas C, Marchetti P, and Bailly C. Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res 66: 3177-3187, 2006.
106. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, and Pedersen PL. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Comm 324: 269-275, 2004.
107. Koobs DH. Phosphate mediation of the Crabtree and Pasteur effects. Science 178: 127-133, 1972.
108. Koppenol WH, Bounds PL, and Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325-337, 2011.
109. Kroemer G, Galluzzi L, and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99-163, 2007.
110. Kudin AP, Bimpong-Buta NY, Vielhaber S, Elger CE, and Kunz WS. Characterization of superoxide-producing sites in isolated brain mitochondria. J Biol Chem 279: 4127-4135, 2004.
111. Kussmaul L and Hirst J. The mechanism of superoxide production by NADH:ubiquinone oxidoreductase (complex I) from bovine heart mitochondria. Proc Natl Acad Sci USA 103: 7607-7612, 2006.
112. Kwong JQ, Henning MS, Starkov AA, and Manfredi G. The mitochondrial respiratory chain is a modulator of apoptosis. J Cell Biol 179: 1163-1177, 2007.
113. Lambert AJ and Brand MD. Inhibitors of the quinonebinding site allow rapid superoxide production from mitochondrial NADH:ubiquinone oxidoreductase (complex I). J Biol Chem 279: 39414-39420, 2004.
114. Lampidis TJ, Bernal SD, Summerhayes IC, and Chen LB. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res 43: 716-720, 1983.
115. Le SB, Hailer MK, Buhrow S, Wang Q, Flatten K, Pediaditakis P, Bible KC, Lewis LD, Sausville EA, Pang YP, Ames MM, Lemasters JJ, Holmuhamedov EL, and Kaufmann SH. Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 282: 8860-8872, 2007.
116. Lee HC, Chang CM, and Chi CW. Somatic mutations of mitochondrial DNA in aging and cancer progression. Ageing Res Rev 9 Suppl 1: S47-58, 2010.
117. Lee HY, Oh SH, Woo JK, Kim WY, Van Pelt CS, Price RE, Cody D, Tran H, Pezzuto JM, Moriarty RM, and Hong WK. Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis. J Natl Cancer Inst 97: 1695-1699, 2005.
118. Lei W, Xie J, Hou Y, Jiang G, Zhang H, Wang P, Wang X, and Zhang B. Mitochondria-targeting properties and photodynamic activities of porphyrin derivatives bearing cationic pendant. J Photochem Photobiol B 98: 167-171, 2010.
119. Leist M, Single B, Castoldi AF, Kuhnle S, and Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med 185: 1481-1486, 1997.
120. Lemarie A and Grimm S. Mitochondrial respiratory chain complexes: Apoptosis sensors mutated in cancer? Oncogene, 2011.
121. Lemarie A, Huc L, Pazarentzos E, Mahul-Mellier AL, and Grimm S. Specific disintegration of complex II succinate: ubiquinone oxidoreductase links pH changes to oxidative stress for apoptosis induction. Cell Death Differ 18: 338-349, 2011.
122. Lessene G, Czabotar PE, and Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7: 989-1000, 2008.
123. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, Watanabe KA, and Perrino FW. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA 93: 3592-3597, 1996.
124. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, and Robinson JP. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 278: 8516-8525, 2003.
125. Liot G, Bossy B, Lubitz S, Kushnareva Y, Sejbuk N, and Bossy-Wetzel E. Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA-and ROS-dependent pathway. Cell Death Differ 16: 899-909, 2009.
126. Liu X, Luo X, Shi Y, Zhu GD, Penning T, Giranda VL, and Luo Y. Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol Ther 7: 934-941, 2008.
127. Lust S, Vanhoecke B, M VANG, Boelens J, H VANM, Kaileh M, Vanden Berghe W, Haegeman G, Philippe J, Bracke M, and Offner F. Xanthohumol activates the proapoptotic arm of the unfolded protein response in chronic lymphocytic leukemia. Anticancer Res 29: 3797-3805, 2009.
128. Madesh M and Hajnoczky G. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J Cell Biol 155: 1003-1015, 2001.
129. Maklashina E and Cecchini G. The quinone-binding and catalytic site of complex II. Biochim Biophys Acta 1797: 3047-3056, 2010.
130. Mathupala SP, Ko YH, and Pedersen PL. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25: 4777-4786, 2006.
131. Matsuzawa A and Ichijo H. Redox control of cell fate by MAP kinase: Physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochim Biophys Acta 1780: 1325-1336, 2008.
132. Mattarei A, Biasutto L, Marotta E, De Marchi U, Sassi N, Garbisa S, Zoratti M, and Paradisi C. A mitochondriotropic derivative of quercetin: A strategy to increase the effectiveness of polyphenols. Chembiochem 9: 2633-2642, 2008.
133. Mehta A and Shaha C. Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: Complex II inhibition results in increased pentamidine cytotoxicity. J Biol Chem 279: 11798-11813, 2004.
134. Miller WH, Jr. Molecular targets of arsenic trioxide in malignant cells. Oncologist 7: 14-19, 2002.
135. Miranda CL, Stevens JF, Helmrich A, Henderson MC, Rodriguez RJ, Yang YH, Deinzer ML, Barnes DW, and Buhler DR. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Food Chem Toxicol 37: 271-285, 1999.
136. Miyadera H, Shiomi K, Ui H, Yamaguchi Y, Masuma R, Tomoda H, Miyoshi H, Osanai A, Kita K, and Omura S. Atpenins, potent and specific inhibitors of mitochondrial complex II (succinate-ubiquinone oxidoreductase). Proc Natl Acad Sci USA 100: 473-477, 2003.
137. Miyako K, Kai Y, Irie T, Takeshige K, and Kang D. The content of intracellular mitochondrial DNA is decreased by 1-methyl-4-phenylpyridinium ion (MPP+ ). J Biol Chem 272: 9605-9608, 1997.
138. Modica-Napolitano JS and Aprille JR. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res 47: 4361-4365, 1987.
139. Modica-Napolitano JS and Aprille JR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49: 63-70, 2001.
140. Moncada S and Erusalimsky JD. Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat Rev Mol Cell Biol 3: 214-220, 2002.
141. Monteiro R, Calhau C, Silva AO, Pinheiro-Silva S, Guerreiro S, Gartner F, Azevedo I, and Soares R. Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J Cell Biochem 104: 1699-1707, 2008.
142. Moreira PI, Custodio J, Moreno A, Oliveira CR, and Santos MS. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J Biol Chem 281: 10143-10152, 2006.
143. Mukhopadhyay I, Sausville EA, Doroshow JH, and Roy KK. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: Signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. J Biol Chem 281: 37330-37344, 2006.
144. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 417: 1-13, 2009.
145. Murphy MP and Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Ann Rev Pharmacol Toxicol 47: 629-656, 2007.
146. Nadanaciva S, Bernal A, Aggeler R, Capaldi R, and Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicol In Vitro 21: 902-911, 2007.
147. Nair AS, Shishodia S, Ahn KS, Kunnumakkara AB, Sethi G, and Aggarwal BB. Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. J Immunol 177: 5612-5622, 2006.
148. Nakamura Y, Kawakami M, Yoshihiro A, Miyoshi N, Ohigashi H, Kawai K, Osawa T, and Uchida K. Involvement of the mitochondrial death pathway in chemopreventive benzyl isothiocyanate-induced apoptosis. J Biol Chem 277: 8492-8499, 2002.
149. Neuzil J, Dong LF, Ramanathapuram L, Hahn T, Chladova M, Wang XF, Zobalova R, Prochazka L, Gold M, Freeman R, Turanek J, Akporiaye ET, Dyason JC, and Ralph SJ. Vitamin E analogues as a novel group of mitocans: Anticancer agents that act by targeting mitochondria. Mol Aspects Med 28: 607-645, 2007.
150. Neuzil J and Massa H. Hepatic processing determines dual activity of alpha-tocopheryl succinate: A novel paradigm for a shift in biological activity due to pro-vitaminto-vitamin conversion. Biochem Biophys Res Commun 327: 1024-1027, 2005.
151. Neuzil J, Swettenham E, Wang XF, Dong LF, and Stapelberg M. Alpha-Tocopheryl succinate inhibits angiogenesis by disrupting paracrine FGF2 signaling. FEBS Lett 581: 4611-4615, 2007.
152. Neuzil J, Tomasetti M, Mellick AS, Alleva R, Salvatore BA, Birringer M, and Fariss MW. Vitamin E analogues: A new class of inducers of apoptosis with selective anticancer effects. Curr Cancer Drug Targets 4: 355-372, 2004.
153. Neuzil J, Tomasetti M, Zhao Y, Dong LF, Birringer M, Wang XF, Low P, Wu K, Salvatore BA, and Ralph SJ. Vitamin E analogs, a novel group of "mitocans," as anticancer agents: The importance of being redox-silent. Mol Pharmacol 71: 1185-1199, 2007.
154. Neuzil J, Weber T, Gellert N, and Weber C. Selective cancer cell killing by alpha-tocopheryl succinate. Br J Cancer 84: 87-89, 2001.
155. Neuzil J, Weber T, Schroder A, Lu M, Ostermann G, Gellert N, Mayne GC, Olejnicka B, Negre-Salvayre A, Sticha M, Coffey RJ, and Weber C. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: Molecular pathways and structural requirements. FASEB J 15: 403-415, 2001.
156. Oh SH, Woo JK, Jin Q, Kang HJ, Jeong JW, Kim KW, Hong WK, and Lee HY.
157. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, Jin Q, Hong SS, Park HJ, Suh YG, Kim KW, Hong WK, and Lee HY. Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99: 949-961, 2007.
158. Okubo T, Yokoyama Y, Kano K, and Kano I. Molecular mechanism of cell death induced by the antioxidant tertbutylhydroxyanisole in human monocytic leukemia U937 cells. Biol Pharm Bull 27: 295-302, 2004.
159. Okun JG, Lummen P, and Brandt U. Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase). J Biol Chem 274: 2625-2630, 1999.
160. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, and Johnson DE. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2-and Bcl-X(L)-mediated apoptosis resistance. Mol Cancer Ther 4: 23-31, 2005.
161. Osipo C, Gajdos C, Cheng D, and Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol 93: 249-256, 2005.
162. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, and Funk RH. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5: e8762, 2010.
163. Papadopoulou LC and Tsiftsoglou AS. Mitochondrial cytochrome c oxidase as a target site for daunomycin in K-562 cells and heart tissue. Cancer Res 53: 1072-1078, 1993.
164. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Jr., Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, and Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812, 2008.
165. Peczkowska M, Cascon A, Prejbisz A, Kubaszek A, Cwikla BJ, Furmanek M, Erlic Z, Eng C, Januszewicz A, and Neumann HP. Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab 4: 111-115, 2008.
166. Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, and Huang P. Inhibition of mitochondrial respiration: A novel strategy to enhance druginduced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 278: 37832-37839, 2003.
167. Prochazka L, Dong LF, Valis K, Freeman R, Ralph SJ, Turanek J, and Neuzil J. Alpha-Tocopheryl succinate causes mitochondrial permeabilization by preferential formation of Bak channels. Apoptosis 15: 782-794, 2010.
168. Propper DJ, Braybrooke JP, Taylor DJ, Lodi R, Styles P, Cramer JA, Collins WC, Levitt NC, Talbot DC, Ganesan TS, and Harris AL. Phase I trial of the selective mitochondrial toxin MKT077 in chemo-resistant solid tumours. Ann Oncol 10: 923-927, 1999.
169. Ralph SJ and Neuzil J. Mitochondria as targets for cancer therapy. Mol Nutr Food Res 53: 9-28, 2009.
170. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, and Moreno-Sanchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 31: 29-59, 2010.
171. Reed GA, Sunega JM, Sullivan DK, Gray JC, Mayo MS, Crowell JA, and Hurwitz A. Single-dose pharmacokinetics and tolerability of absorption-enhanced 3,3'-diindolylmethane in healthy subjects. Cancer Epidemiol Biomarkers Prev 17: 2619-2624, 2008.
172. Safe S, Papineni S, and Chintharlapalli S. Cancer chemotherapy with indole-3-carbinol, bis(3'-indolyl)methane and synthetic analogs. Cancer Lett 269: 326-338, 2008.
173. Sahu RP, Zhang R, Batra S, Shi Y, and Srivastava SK. Benzyl isothiocyanate-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of MAPK in human pancreatic cancer cells. Carcinogenesis 30: 1744-1753, 2009.
174. Salomon AR, Voehringer DW, Herzenberg LA, and Khosla C. Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F(0)F(1)-ATPase. Proc Natl Acad Sci USA 97: 14766-14771, 2000.
175. Salomon AR, Voehringer DW, Herzenberg LA, and Khosla C. Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase. Chem Biol 8: 71-80, 2001.
176. Saraste M. Oxidative phosphorylation at the fin de siecle. Science 283: 1488-1493, 1999.
177. Sasaki R, Suzuki Y, Yonezawa Y, Ota Y, Okamoto Y, Demizu Y, Huang P, Yoshida H, Sugimura K, and Mizushina Y. DNA polymerase gamma inhibition by vitamin K3 induces mitochondria-mediated cytotoxicity in human cancer cells. Cancer Sci 99: 1040-1048, 2008.
178. Scheffler I. Mitochondria, Second Edition Hoboken, New Jersey, USA: John Wiley & Sons, Inc.; 2008.
179. Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM, Berlis A, Brink I, Cybulla M, Muresan M, Walter MA, Forrer F, Valimaki M, Kawecki A, Szutkowski Z, Schipper J, Walz MK, Pigny P, Bauters C, Willet-Brozick JE, Baysal BE, Januszewicz A, Eng C, Opocher G, and Neumann HP. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294: 2057-2063, 2005.
180. Shaban H, Gazzotti P, and Richter C. Cytochrome c oxidase inhibition by N-retinyl-N-retinylidene ethanolamine, a compound suspected to cause age-related macula degeneration. Arch Biochem Biophys 394: 111-116, 2001.
181. Shiau CW, Huang JW, Wang DS, Weng JR, Yang CC, Lin CH, Li C, and Chen CS. Alpha-Tocopheryl succinate induces apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 function. J Biol Chem 281: 11819-11825, 2006.
182. Shun MC, Yu W, Park SK, Sanders BG, and Kline K. Downregulation of epidermal growth factor receptor expression contributes to alpha-TEA's proapoptotic effects in human ovarian cancer cell lines. J Oncol 2010: 824571, 2010.
183. Sibrian-Vazquez M, Nesterova IV, Jensen TJ, and Vicente MG.Mitochondria targeting by guanidine-and biguanidineporphyrin photosensitizers. BioconjugChem19: 705-713, 2008.
184. Simons AL, Ahmad IM,MattsonDM, Dornfeld KJ, and Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67: 3364-3370, 2007.
185. Slapke J, Schewe T, Hummel S, Winkler J, and Kopf M. Lung strips from guinea pigs as test system for lipoxygenase inhibitors. Inhibition of arachidonic acid-induced contractions by 3-t-butyl-4-hydroxyanisole and nordihydroguaiaretic acid. Biomed Biochim Acta 42: 1309-1318, 1983.
186. Soller M, Drose S, Brandt U, Brune B, and von Knethen A. Mechanism of thiazolidinedione-dependent cell death in Jurkat T cells. Mol Pharmacol 71: 1535-1544, 2007.
187. Stapelberg M, Gellert N, Swettenham E, Tomasetti M, Witting PK, Procopio A, and Neuzil J. Alpha-tocopheryl succinate inhibits malignant mesothelioma by disrupting the fibroblast growth factor autocrine loop: Mechanism and the role of oxidative stress. J Biol Chem 280: 25369-25376, 2005.
188. Strathmann J, Klimo K, Sauer SW, Okun JG, Prehn JH, and Gerhauser C. Xanthohumol-induced transient superoxide anion radical formation triggers cancer cells into apoptosis via a mitochondria-mediated mechanism. FASEB J 24: 2938-2950, 2010.
189. Suen DF, Norris KL, and Youle RJ. Mitochondrial dynamics and apoptosis. Genes Dev 22: 1577-1590, 2008.
190. Summerhayes IC, Lampidis TJ, Bernal SD, Nadakavukaren JJ, Nadakavukaren KK, Shepherd EL, and Chen LB. Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci USA 79: 5292-5296, 1982.
191. Sun F, Huo X, Zhai Y, Wang A, Xu J, Su D, Bartlam M, and Rao Z. Crystal structure of mitochondrial respiratory membrane protein complex II. Cell 121: 1043-1057, 2005.
192. Suter M, Reme C, Grimm C, Wenzel A, Jaattela M, Esser P, Kociok N, Leist M, and Richter C. Age-related macular degeneration. The lipofusion component N-retinyl-Nretinylidene ethanolamine detaches proapoptotic proteins from mitochondria and induces apoptosis in mammalian retinal pigment epithelial cells. J BiolChem275: 39625-39630, 2000.
193. Szatrowski TP and Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51: 794-798, 1991.
194. Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, Kofler R, Csordas A, and Greil R. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis pag a novel mitochondrial pathway controlled by Bcl-2. FASEB J 15: 1613-1615, 2001.
195. Tocilescu MA, Fendel U, Zwicker K, Kerscher S, and Brandt U. Exploring the ubiquinone binding cavity of respiratory complex I. J Biol Chem 282: 29514-29520, 2007.
196. Trachootham D, Alexandre J, and Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov 8: 579-591, 2009.
197. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, and Huang P. Effective elimination of fludarabineresistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112: 1912-1922, 2008.
198. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, and Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by betaphenylethyl isothiocyanate. Cancer Cell 10: 241-252, 2006.
199. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, and Elmore SW. ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428, 2008.
200. Twombly R. Cancer surpasses heart disease as leading cause of death for all but the very elderly. J Natl Cancer Inst 97: 330-331, 2005.
201. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, and Hockenbery DM. Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol 3: 183-191, 2001.
202. Udeani GO, Gerhauser C, Thomas CF, Moon RC, Kosmeder JW, Kinghorn AD, Moriarty RM, and Pezzuto JM. Cancer chemopreventive activity mediated by deguelin, a naturally occurring rotenoid. Cancer Res 57: 3424-3428, 1997.
203. Umeda S, Muta T, Ohsato T, Takamatsu C, Hamasaki N, and Kang D. The D-loop structure of human mtDNA is destabilized directly by 1-methyl-4- phenylpyridinium ion (MPP+ ), a parkinsonism-causing toxin. Eur J Biochem 267: 200-206, 2000.
204. Valis K, Prochazka L, Boura E, Chladova J, Obsil T, Rohlena J, Truksa J, Dong LF, Ralph SJ, and Neuzil J. Hippo/Mst1 stimulates transcription of the proapoptotic mediator NOXA in a FoxO1-dependent manner. Cancer Res 71: 946-954, 2011.
205. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, and Huang DC. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399, 2006.
206. Vander Heiden MG, Cantley LC, and Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324: 1029-1033, 2009.
207. Wang F, Ogasawara MA, and Huang P. Small mitochondria-targeting molecules as anticancer agents. Mol Aspects Med 31: 75-92, 2010.
208. Wang XF, Dong L, Zhao Y, Tomasetti M, Wu K, and Neuzil J. Vitamin E analogues as anticancer agents: Lessons from studies with alpha-tocopheryl succinate. Mol Nutr Food Res 50: 675-685, 2006.
209. Warin R, Chambers WH, Potter DM, and Singh SV. Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate. Cancer Res 69: 9473-9480, 2009.
210. Warin R, Xiao D, Arlotti JA, Bommareddy A, and Singh SV. Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate. Mol Carcinog 49: 500-507, 2010.
211. Weber T, Dalen H, Andera L, Negre-Salvayre A, Auge N, Sticha M, Lloret A, Terman A, Witting PK, Higuchi M, Plasilova M, Zivny J, Gellert N, Weber C, and Neuzil J. Mitochondria play a central role in apoptosis induced by alpha-tocopheryl succinate, an agent with antineoplastic activity: Comparison with receptor-mediated pro-apoptotic signaling. Biochemistry 42: 4277-4291, 2003.
212. Wiatrak BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 11: 433-441, 2003.
213. Wijayaratne AL, Nagel SC, Paige LA, Christensen DJ, Norris JD, Fowlkes DM, and McDonnell DP. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 140: 5828-5840, 1999.
214. Wolvetang EJ, Johnson KL, Krauer K, Ralph SJ, and Linnane AW. Mitochondrial respiratory chain inhibitors induce apoptosis. FEBS Lett 339: 40-44, 1994.
215. Xia D, Yu CA, Kim H, Xia JZ, Kachurin AM, Zhang L, Yu L, and Deisenhofer J. Crystal structure of the cytochrome bc1 complex from bovine heart mitochondria. Science 277: 60-66, 1997.
216. Xiao D, Powolny AA, and Singh SV. Benzyl isothiocyanate targets mitochondrial respiratory chain to trigger reactive oxygen species-dependent apoptosis in human breast cancer cells. J Biol Chem 283: 30151-30163, 2008.
217. Xu K and Thornalley PJ. Involvement of glutathione metabolism in the cytotoxicity of the phenethyl isothiocyanate and its cysteine conjugate to human leukaemia cells in vitro. Biochem Pharmacol 61: 165-177, 2001.
218. Yang YM, Conaway CC, Chiao JW, Wang CX, Amin S, Whysner J, Dai W, Reinhardt J, and Chung FL. Inhibition of benzo(a)pyrene-induced lung tumorigenesis in A/J mice by dietary N-acetylcysteine conjugates of benzyl and phenethyl isothiocyanates during the postinitiation phase is associated with activation of mitogen-activated protein kinases and p53 activity and induction of apoptosis. Cancer Res 62: 2-7, 2002.
219. Yankovskaya V, Horsefield R, Tornroth S, Luna-Chavez C, Miyoshi H, Leger C, Byrne B, Cecchini G, and Iwata S. Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 299: 700-704, 2003.
220. You KR, Wen J, Lee ST, and Kim DG. Cytochrome c oxidase subunit III: A molecular marker for N-(4-hydroxyphenyl) retinamise-induced oxidative stress in hepatoma cells. J Biol Chem 277: 3870-3877, 2002.
221. Youle RJ and Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
222. Yu C, Rahmani M, Almenara J, Sausville EA, Dent P, and Grant S. Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK-and AKT-dependent process. Oncogene 23: 1364-1376, 2004.
223. Zamaraeva MV, Sabirov RZ, Maeno E, Ando-Akatsuka Y, Bessonova SV, and Okada Y. Cells die with increased cytosolic ATP during apoptosis: A bioluminescence study with intracellular luciferase. Cell Death Differ 12: 1390-1397, 2005.
224. Zeitlin BD, Zeitlin IJ, and Nor JE. Expanding circle of inhibition: Small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol 26: 4180-4188, 2008.
225. Zhang JG, Nicholls-Grzemski FA, Tirmenstein MA, and Fariss MW. Vitamin E succinate protects hepatocytes against the toxic effect of reactive oxygen species generated at mitochondrial complexes I and III by alkylating agents. Chem Biol Interact 138: 267-284, 2001.
226. Zhang JG, Tirmenstein MA, Nicholls-Grzemski FA, and Fariss MW. Mitochondrial electron transport inhibitors cause lipid peroxidation-dependent and-independent cell death: protective role of antioxidants. Arch Biochem Biophys 393: 87-96, 2001.
227. Zheng J and Ramirez VD. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem Biophys Res Commun 261: 499-503, 1999.
228. Zhivotovsky B, Galluzzi L, Kepp O, and Kroemer G. Adenine nucleotide translocase: A component of the phylogenetically conserved cell death machinery. Cell Death and Differentiation 16: 1419-1425, 2009.
229. Zini R, Morin C, Bertelli A, Bertelli AA, and Tillement JP. Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res 25: 87-97, 1999.